Actively Recruiting
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Led by European Institute of Oncology · Updated on 2024-03-20
40
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.
CONDITIONS
Official Title
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of castration-resistant prostate cancer
- Presence of single or multiple bone metastases
- Life expectancy greater than 6 months
- No active malignancy other than prostate cancer
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Absolute contraindications to WB-MRI, CT scan, or bone scintigraphy
- Prior radical treatment targeting the only site of metastatic disease (e.g., Cyberknife to solitary lesion)
- Psychological, familial, social, or geographical factors that could prevent following the study protocol, as discussed during informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IEO Istituto Europeo di Oncologia
Milan, Italy, 20141
Actively Recruiting
Research Team
G
Giuseppe Petralia, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here